Depression and the risk of hospitalization in type 2 diabetes patients: A nested case-control study accounting for non-persistence to antidiabetic treatment.

Diabetes Metab

Axe Santé des Populations et Pratiques Optimales en Santé (SP-POS), Centre de recherche du CHU de Quebec-Université Laval, 1050 chemin Ste-Foy, Quebec City, QC, Canada; Department of Health Sciences, Université du Québec à Rimouski, 1595 boulevard Alphonse-Desjardins, Lévis, QC, Canada. Elect

Published: July 2022


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Introduction: Depression is one of the most common comorbidities of type 2 diabetes. The relationship between these two diseases seems to be bidirectional. Both conditions separately lead to significant morbidity and mortality, including hospitalization. Moreover, depression is associated with non-persistence with antidiabetic drugs.

Objectives: To measure the effect of depression on morbidity and particularly on all-cause, diabetes-related, cardiovascular-related and major cardiovascular events-related hospitalization, adjusting for non-persistence to antidiabetic drugs and other confounders.

Methods: We performed a nested case-control study within a cohort of type 2 diabetic individuals initiating antidiabetic drugs. Using the health administrative data of the province of Quebec, Canada, we identified all-cause, diabetes-related, cardiovascular-related and major cardiovascular hospitalizations during a maximum follow-up of eight years after the initiation of antidiabetic drug treatment. A density sampling method matched all cases with up to 10 controls by age, sex, and the Elixhauser comorbidity index. The effect of depression on hospitalization was estimated using conditional logistic regressions adjusting for non-persistence to antidiabetic drug treatment and other variables.

Results: We identified 41,550 all-cause hospitalized cases, of which 34,437 were related to cardiovascular (CV) diseases, 29,584 to diabetes, and 13,867 to major CV events. Depression was diagnosed in 2.51% of all-cause hospitalizations and 1.16% of matched controls. 69.11% of cases and 72.59% of controls were on metformin monotherapy. The majority (71.62% vs 75.02%, respectively) stayed on metformin monotherapy without adding or switching drugs during follow-up. Non-persistence was at similar rates (about 30%) in both groups. In the multivariable analyses, depression was associated with an increased risk for all-cause hospitalizations, with odds ratios (ORs) ranging from 2.21 (95% CI: 2.07-2.37) to 1.32 (95% CI: 1.22-1.44) according to the model adjustment (from the univariate to the fully adhjusted).

Conclusion: Depression increased the risk of all-cause hospitalizations among patients treated for diabetes, even after accounting for non-persistence and other potentially confounding factors. These results stress the impact of depression on diabetic patients' use of health care resources.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.diabet.2022.101334DOI Listing

Publication Analysis

Top Keywords

non-persistence antidiabetic
16
all-cause hospitalizations
12
depression
9
type diabetes
8
nested case-control
8
case-control study
8
accounting non-persistence
8
depression associated
8
all-cause diabetes-related
8
diabetes-related cardiovascular-related
8

Similar Publications

Effect of initial combination therapy vs. step-therapy on adherence and persistence in drug naïve type 2 diabetes patients.

J Diabetes Complications

September 2025

Department of Pharmaceutical Health Outcomes and Policy, College of Pharmacy, University of Houston, Houston, TX, USA. Electronic address:

Background/objectives: Emerging evidence supports the early use of intensive combination treatments among type 2 diabetes (T2D) patients for rapid and sustained glycemic control. However, the impact of initial combination therapy on treatment adherence and persistence has not been explored. Therefore, we aimed to compare adherence and persistence to antidiabetic treatments between patients receiving initial combination therapy vs.

View Article and Find Full Text PDF

Adherence and persistence to novel glucose-lowering medications in persons with type 2 diabetes mellitus undergoing routine care.

Diabetes Res Clin Pract

July 2024

Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm Sweden; Renal Medicine, Danderyd Hospital, Stockholm, Sweden. Electronic address:

Aims: To assess adherence and persistence to sodium-glucose cotransporter-2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP1-RA), and dipeptidyl peptidase-4 inhibitors (DPP4i) in routine care.

Methods: Using retrospective healthcare data from the Stockholm region, Sweden, we evaluated new-users of these agents during 2015-2020. We investigated adherence (≥80 % of days covered by an active supply), persistence (no treatment gap ≥ 60 days), and predictors for non-adherence and non-persistence.

View Article and Find Full Text PDF
Article Synopsis
  • The study evaluated how consistent patients were with basal insulin therapy and how it impacted healthcare usage and costs among adults with type 2 diabetes over a two-year period.
  • Out of nearly 65,000 patients, 56.8% remained consistent with their treatment, while 41.9% adhered to it, leading to fewer hospital visits and lower medical expenses in the second year for those who were persistent and adherent.
  • Prior usage of both oral and injectable diabetes medications increased the likelihood of persistence and adherence to insulin therapy, suggesting that earlier treatment experiences may help improve ongoing commitment to therapy.
View Article and Find Full Text PDF

Type 2 diabetes mellitus (T2DM) is managed with combined lifestyle modifications and antidiabetic drugs, but people on treatment often fail to reach glycaemic control. Adherence is important for achieving optimal glycaemic control, and management of diabetes with drugs is a lifelong process, so understanding adherence through analysis of longitudinal medications data is important. Using retrospective routine health data and metformin dispensing records as a proxy for medication use, we describe longitudinal persistence and adherence to oral diabetes medication in a virtual cohort of 10541 people with diabetes (PLWD) in Khayelitsha subdistrict, Cape Town.

View Article and Find Full Text PDF

Objective: Poor medication adherence remains highly prevalent and adversely affects health outcomes. Patients frequently describe properties of the pills themselves, like size and shape, as barriers, but this has not been evaluated objectively. We sought to determine the extent to which oral medication properties thought to be influential translate into lower objectively-measured adherence.

View Article and Find Full Text PDF